Functional Expression of the Internal Rotenone-Insensitive NADH-Quinone Oxidoreductase (NDI1) Gene of Saccharomyces cerevisiae in Human HeLa Cells

다국어 초록 (Multilingual Abstract)

Many studies propose that dysfunction of mitochondrial proton-translocating NADH-ubiquinone oxidoreductase (complex I) is associated with neurodegenerative disorders, such as Parkinson's disease and Huntington's disease. Mammalian mitochondrial proton-translocating NADH-quinone oxidoreductase (complex I) consists of at least 46 different subunits. In contrast, the NDI1 gene of Saccharomyces cerevisiae is a single subunit rotenone-insensitive NADH-quinone oxidoreductase that is located on the matrix side of the inner mitochondrial membrane. With a recombinant adeno-associated virus vector carrying the NDI1 gene (rAAV-NDI1) as the gene delivery method, we were able to attain high transduction efficiencies even in the human epithelial cervical cancer cells that are difficult to transfect by lipofection or calcium phosphate precipitation methods. Using a rAAV-NDI1, we demonstrated that the Ndi1 enzyme is successfully expressed in HeLa cells. The expressed Ndi1 enzyme was recognized to be localized in mitochondria by confocal immunofluorescence microscopic analyses and immunoblotting. Using digitonin-permeabilized cells, it was shown that the NADH oxidase activity of the NDI1-transduced HeLa cells were not affected by rotenone which is inhibitor of complex I, but was inhibited by flavone and antimycin A. The NDI1-transduced cells were able to grow in media containing rotenone. In contrast, control cells that did not receive the NDI1 gene failed to survive. In particular, in the NDI1-transduced cells, the yeast enzyme becomes integrated into the human respiratory chain. It is concluded that the NDI1 gene provides a potentially useful tool for gene therapy of mitochondrial diseases caused by complex I deficiency.

참고문헌 (Reference)

1 Robbins PD, "Viral vectors for gene therapy" 80 : 35-47, 1998

2 Seo BB, "Use of the NADH-quinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae as a possible cure for complex I defects in human cells" 275 : 37774-37778, 2000

3 Hofhaus G, "Use of polarography to detect respiration defects in cell cultures" 264 : 476-483, 1996

4 Chomyn A, "URF6, last unidentified reading frame of human mtDNA, codes for an NADH dehydrogenase subunit" 234 : 614-618, 1986

5 Manning-Bog AB, "The herbicide paraquat causes up-regulation and aggregation of α-synuclein in mice: paraquat and α-synuclein" 277 : 1641-1644, 2002

6 Yagi T, "The bacterial energy-transducing NADH-quinone oxidoreductases" 1141 : 1-17, 1993

7 Flotte TR, "Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector" 90 : 10613-10617, 1993

8 Chomyn A, "Six unidentified reading frames of human mitochondrial DNA encode components of the respiratory-chain NADH dehydrogenase" 314 : 591-597, 1985

9 Granger DL, "Sites of inhibition of mitochondrial electron transport in macrophage-injured neoplastic cells" 95 : 527-535, 1982

10 Kitajima-Ihara T, "Rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria: the enzyme expressed in Escherichia coli acts as a member of the respiratory chain in the host cells" 421 : 37-40, 1998

11 Guy J, "Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy" 52 : 534-542, 2002

12 Manfredi G, "Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus" 30 : 394-399, 2002

13 Owen R, "Recombinant adenoassociated virus vector-based gene transfer for defects in oxidative metabolism" 11 : 2067-2078, 2000

14 Zolotukhin S, "Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield" 6 : 973-985, 1999

15 de Vries S, "Purification and characterization of a rotenone-insensitive NADH-Q6 oxidoreductase from mitochondria of Saccharomyces cerevisiae" (176) : 377-384, 1988

16 Wu N, "Production of viral vectors for gene therapy applications" 11 : 205-208, 2000

17 de Vries S, "Primary structure and import pathway of the rotenone-insensitive NADH-ubiquinone oxidoreductase of mitochondria from Saccharomyces cerevisiae" 203 : 587-592, 1992

18 Shoffner JM, "Oxidative phosphorylation diseases and mitochondrial DNA mutations diagnosis and treatment" 14 : 535-568, 1994

19 Seo BB, "Molecular remedy of complex I defects: Rotenone-insensitive internal NADH-quinone oxidoreductase of Saccharomyces cerevisiae mitochondria restores the NADH oxidase activity of complex I-deficient mammalian cells" 95 : 9167-9171, 1998

20 Dawson TM, "Molecular pathways of neurodegeneration in Parkinson's disease" 302 : 819-822, 2003

21 Schapira AHV, "Molecular basis of mitochondrial myopathies: Polypeptide analysis in complex I deficiency" 331 : 500-503, 1988

22 Seo BB, "Modulation of oxidative phosphorylation of human kidney 293 cells by transfection with the internal rotenone-insensitive NADHquinone oxidoreductase (NDI1) gene of Saccharomyces cerevisiae" 1412 : 56-65, 1999

23 Sherer TB, "Mechanism of toxicity in rotenone models of Parkinson's disease" 23 : 10756-10764, 2003

24 Klimatcheva E, "Lentiviral vectors and gene therapy" 4 : D481-D496, 1999

25 Buchanan SK, "Large-scale chromatographic purification of F1F0-ATPase and complex I from bovine heart mitochondria" 318 : 343-349, 1996

26 Bai Y, "Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene" 276 : 38808-38813, 2001

27 Marres, CAM, "Isolation and inactivation of the nuclear gene encoding the rotenone-insensitive internal NADH: ubiquinone oxidoreductase of mitochondria from Saccharomyces cerevisiae" 195 : 857-862, 1991

28 Hayashi JI, "Introduction of disease-related mitochondrial DNA deletions into HeLa cells lacking mitochondrial DNA results in mitochondrial dysfunction" 88 : 10614-10618, 1991

29 Naldini L, "In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector" 272 : 263-267, 1996

30 Robinson BH, "Human complex I deficiency: Clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect" 1364 : 271-286, 1998

31 Todd S, "HIV protease as a target for retrovirus vector-mediated gene therapy" 1477 : 168-188, 2000

32 Sherer TB, "Environment, mitochondria, and Parkinson's disease" 8 : 192-197, 2002

33 Wallace DC, "Diseases of the mitochondrial DNA" 61 : 1175-1212, 1992

34 Laemmli UK, "Cleavage of structural proteins during the assembly of the head of bacteriophage T4" 227 : 680-685, 1970

35 Betarbet R, "Chronic systemic pesticide exposure reproduces features of Parkinson’s disease" 3 : 1301-1306, 2000

36 Singer DR, "Atrial natriuretic peptide, blood pressure, and age" 2 : 1394-1395, 1987

37 Trounce IA, "Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines" 264 : 484-509, 1996

38 Snyder RO, "Adeno-associated virus-mediated gene delivery" 1 : 166-175, 1999

39 Muzyczka N, "Adeno-associated virus (AAV) vectors:will they work?" 94 : 1351-, 1994